PULMONARY ARTERIAL HYPERTENSION (PAH)
Clinical trials for PULMONARY ARTERIAL HYPERTENSION (PAH) explained in plain language.
Never miss a new study
Get alerted when new PULMONARY ARTERIAL HYPERTENSION (PAH) trials appear
Sign up with your email to follow new studies for PULMONARY ARTERIAL HYPERTENSION (PAH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Which drug is best for pulmonary hypertensive crisis? new trial aims to find out
Disease control Not yet recruitingThis trial will compare three drugs—dopamine, norepinephrine, and epinephrine—to see which works best for people experiencing a pulmonary hypertensive crisis, a life-threatening spike in blood pressure in the lungs. The study will enroll 75 adults with pulmonary arterial hyperten…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: NA • Sponsor: China National Center for Cardiovascular Diseases • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Lung patients may soon do rehab from home via app
Disease control Not yet recruitingThis study tests whether a 12-week tele-pulmonary rehabilitation program, done at home via an app with a physiotherapist, helps people with chronic lung diseases start and stick with rehab better than going to a center. 90 patients will be randomly assigned to either remote rehab…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: NA • Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New PAH drug IKT-001 moves to Long-Term safety check
Disease control Not yet recruitingThis study is checking the long-term safety of a daily pill called IKT-001 for people with pulmonary arterial hypertension (PAH), a serious lung condition. About 484 adults who have already completed an earlier IKT-001 study will take the drug for an extended period. Researchers …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE3 • Sponsor: Inhibikase Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for PAH patients: Extended-Release tacrolimus enters phase 3 trial
Disease control Not yet recruitingThis Phase 3 study tests VI-0106, an extended-release form of tacrolimus, in 300 people with pulmonary arterial hypertension (PAH) who still have trouble with daily activities despite taking standard PAH medications. Participants will receive either the drug or a placebo for 24 w…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE3 • Sponsor: VIVUS LLC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a daily shot help control rare lung disease?
Disease control Not yet recruitingThis phase 2 trial tests whether adding tiprelestat (elafin) to standard care improves blood flow in the lungs for people with pulmonary arterial hypertension (PAH). About 90 adults with moderate to severe PAH will receive either a daily injection of tiprelestat or a placebo for …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental drug aims to heal damaged lung arteries
Disease control Not yet recruitingThis study will test whether the drug sotatercept can reverse damage to the lung's blood vessels in people with pulmonary arterial hypertension (PAH). Researchers will use special imaging techniques to look inside the arteries and see if they become healthier over 9 months. The s…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: Franz Rischard, DO • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New study eyes selexipag for neglected form of lung hypertension
Disease control Not yet recruitingThis study looks at how well the oral medication selexipag works over the long term for people with a specific type of lung hypertension caused by schistosomiasis (a parasitic infection). Researchers will compare patients who received selexipag as part of routine care to similar …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: Caio Júlio César dos Santos Fernandes • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could stem cells help tiniest babies breathe easier?
Disease control Not yet recruitingThis early study tests a single dose of stem cells (PNEUMOSTEM®) given into the windpipe of very premature babies with high blood pressure in their lungs. The goal is to see if it is safe and might improve breathing, reduce time on a ventilator, and lower the need for oxygen. Onl…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE1 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Triple threat: new combo therapy aims to tackle rare lung disease
Disease control Not yet recruitingThis phase 2 trial tests whether a triple combination of three drugs—sotatercept, an endothelin receptor antagonist, and a phosphodiesterase-5 inhibitor—can improve blood flow in the lungs of people newly diagnosed with pulmonary arterial hypertension (PAH). The study will enroll…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE2 • Sponsor: Philipps University Marburg • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New injectable drug hopes to boost heart function in PAH patients
Disease control Not yet recruitingThis study tests whether adding an injectable medication called treprostinil to standard oral therapy can improve heart function in people with intermediate-risk pulmonary arterial hypertension (PAH). About 32 adults will receive the drug for 3 months, with heart scans and walkin…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 26, 2026 18:35 UTC
-
PAH patients may ditch frequent inhalers for a Once-Daily pill
Symptom relief Not yet recruitingThis study follows 32 adults with pulmonary arterial hypertension (PAH) whose doctors decide to switch them from inhaled iloprost (taken several times a day) to oral selexipag (a pill). Researchers will use questionnaires to see if the switch improves quality of life, treatment s…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: University of Sao Paulo General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
New PET scans reveal how experimental drug reshapes lung vessels in PAH
Knowledge-focused Not yet recruitingThis pilot study will use special PET/CT scans to see how the experimental drug sotatercept affects blood vessel remodeling in the lungs and heart of people with pulmonary arterial hypertension (PAH). About 15 adults with PAH will receive sotatercept and have imaging at the start…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New survey aims to better understand life with lung disease
Knowledge-focused Not yet recruitingThis study will create and test a new questionnaire to measure quality of life in Chinese patients with pulmonary arterial hypertension (PAH), a serious lung condition. Researchers will work with 300 adults to ensure the tool is accurate and useful for doctors and health policy. …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: Chinese Pulmonary Vascular Disease Research Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Toxins in hair and urine: could they trigger rare lung disease?
Knowledge-focused Not yet recruitingThis study looks at whether environmental toxins, drugs, and workplace exposures play a role in causing pulmonary arterial hypertension (PAH), a rare and serious lung condition. Researchers will compare 150 newly diagnosed patients with PAH to those with another form of pulmonary…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Scientists hunt for genes behind rare lung complication in liver bypass patients
Knowledge-focused Not yet recruitingThis study aims to find genetic variants that may explain why some people with a rare liver bypass condition (congenital portosystemic shunt) develop a serious lung complication called portopulmonary hypertension. Researchers will analyze blood samples from 120 patients and their…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: Prof. Valérie Mc Lin • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Study aims to map how patients and caregivers find information about pulmonary hypertension
Knowledge-focused Not yet recruitingThis study uses a short questionnaire to learn where patients with pulmonary hypertension and their caregivers search for health information, what topics they look for, how satisfied they are, and which sources they trust most. Researchers will enroll 100 adults in Brazil. The go…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: University of Sao Paulo General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC